Teclistamab is a first-in-class BCMA×CD3 bispecific antibody jointly developed by Janssen, a Johnson & Johnson Company, and Genmab. The therapy redirects T cells toward BCMA-expressing myeloma cells, enabling targeted immune-mediated killing. Following its regulatory approvals in RRMM, teclistamab has become one of the most widely utilized BCMA-directed bispecific antibodies globally.

EMN30/MajesTEC-4 was designed to evaluate whether teclistamab alone or in combination with lenalidomide could improve outcomes as maintenance therapy following autologous stem cell transplantation. The updated safety run-in analysis included three cohorts evaluating different teclistamab-based maintenance approaches.

Safety Outcomes-

• Grade 3/4 TEAEs occurred in 100%, 96.9%, and 66.7% of patients in Cohorts 1, 2, and 3; Grade 3/4 neutropenia was most common (93.8%, 78.1%, and 63.3%). 

• Any Grade infections occurred in 96.9%, 87.5%, and 90.0% of patients, respectively; Grade 3/4 infections occurred in 37.5%, 34.4%, and 26.7%. 

• Hypogammaglobulinemia incidence was 96.9%, 87.5%, and 93.3% in Cohorts 1, 2, and 3; all of these patients received ≥1 dose of IgG replacement. 

• CRS rate was 44.7% (Grade 1/2: 38.3%/6.4%); all events resolved; none led to treatment discontinuation. No ICANS occurred. 

• Nine patients had TEAEs leading to treatment discontinuation; 2 patients in Cohort 2 had fatal TEAEs (1 due to infection, patients did not receive IgG during hospitalization). 

• Two non-TEAE deaths occurred.

KOL Insights-

“The ability to achieve near-universal complete responses and exceptionally high MRD-negative rates after transplant suggests BCMA-directed therapy may have meaningful utility much earlier in the disease course.”– Expert Opinion

“The safety profile appears consistent with prior teclistamab experience, while the depth of response observed in the maintenance setting is particularly encouraging.”– Expert Opinion

Conclusion-

Multiple myeloma remains the second most common hematologic malignancy worldwide, and despite significant advances in induction therapy and stem cell transplantation, disease relapse remains inevitable for many patients. Maintenance therapy has therefore become a critical component of long-term disease management.

The updated results from EMN30/MajesTEC-4 demonstrate that teclistamab, either alone or combined with lenalidomide, can be administered in the post-transplant setting with manageable toxicity and sustained treatment exposure. The substantial deepening of responses, high rates of MRD-negative complete remission, and encouraging progression-free survival outcomes support continued evaluation of BCMA-directed maintenance therapy. If confirmed in the randomized phase of the study, teclistamab-based maintenance could represent an important evolution in the treatment strategy for newly diagnosed multiple myeloma.